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Abstract
Rationale Inhibition of the glycine transporter 1 (GlyT1)
activity increases extra-cellular glycine availability in the
CNS. At glutamatergic synapses, increased binding to the
glycine-B site located in the N-methyl-D-aspartate receptor
(NMDAR) can enhance neurotransmission via NMDARs.
Systemic treatment of 2-chloro-N-[(S)-phenyl [(2S)-piperidin-
2-yl] methyl]-3-trifluoromethyl benzamide, monohydro-
chloride (SSR504734), a selective GlyT1 inhibitor, is
effective against social recognition impairment induced by
neonatal phencyclidine treatment and enhances pre-pulse
inhibition in a mouse strain (DBA/2) with intrinsic sensori-
motor gating deficiency, suggesting that SSR504734 may be
an effective cognitive enhancer.
Objective The objective of the study was to examine if
SSR504734 exhibits a promnesic effect on working
memory function in wild-type C57BL/6 mice using an
automatic continuous alternation task.
Materials and methods Hungry mice were trained to
alternate their nose pokes between two food magazines
across successive discrete trials in an operant chamber in
order to obtain food reward. Correct choice on a given trial
thus followed a non-matching or win-shift rule in relation to
the preceding trial, with manipulation of the demand on
memory retention, by varying the delay between successive
trials.
Results Pre-treatment with SSR504734 (30 mg/kg, i.p.)
improved choice accuracy when the delay from the
previous trial was extended to 12–16 s. Furthermore, a
dose–response analysis (3, 10, 30 mg/kg) revealed a clear
dose-dependent efficacy of the drug: 3 mg/kg was without
effect, whilst 10 mg/kg led to an intermediate enhancement
in performance.
Conclusion The present findings represent the first demon-
stration of the promnesic effects of SSR504734 under
normal physiological conditions, lending further support to
the suggestion of its potential as a cognitive enhancer.
Keywords Glycine transporter 1 .Memory . Learning .
NMDA receptor .Working memory
Introduction
The hypothesis thatN-methyl-D-aspartate receptor (NMDAR)
activation plays a central role in the neural plasticity
underlying learning and memory (Morris 1989, Collingridge
and Bliss 1995, Tang et al. 1999) has generated growing
interest in agents that can enhance NMDAR activation as
potential therapeutics against cognitive deficits caused by
diseases and their potential use as cognitive enhancers in
otherwise healthy individuals (Sahakian and Morein-Zamir,
2007). Because the simultaneous binding of both glutamate
and glycine to NMDAR is mandatory for NMDAR ion
channel opening (McBain and Mayer 1994), both the
glutamate binding site located on the NMDAR NR2 subunit
and the glycine binding site (glycine-B site) on the NR1
subunit constitute potential targets to enhance NMDAR
activation. Due to a number of undesirable side effects
associated with competitive NMDAR agonists acting at the
glutamate site (Danysz and Parsons 1998), a current focus is
on targeting the glycine-B site. It has long been suggested
that the glycine-B sites are not saturated under physiological
conditions (Danysz et al. 1987, 1989), and the subsequent
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confirmation of this hypothesis (Berger et al. 1998; Bergeron
et al. 1998, Chen et al. 2003) has led to the suggestion that
NMDAR activation can be facilitated by increasing glycine-B
site occupancy. In support of this hypothesis, glycine-B site
agonist (glycine and D-serine) as well as partial agonist
(D-cycloserine) treatment can improve the therapeutic efficacy
of conventional anti-psychotic medications against negative
and cognitive symptoms of schizophrenia (Coyle and Tsai
2004, Heresco-Levy 2000) that are closely linked to
NMDAR hypofunction (Olney and Farber 1995). Whilst
there is no convincing evidence that glycine-B site agonists
or partial agonists improve cognitive functions in healthy
humans, this has however been demonstrated in laboratory
animals in tests of associative learning, working memory,
reversal learning, and familiarity judgement (Monahan et al.
1989, Pussinen and Sirviö 1999, Duffy et al. 2008, Nunnink
et al. 2007, Zlomuzica et al. 2007).
One potential limit to the use of glycine or D-serine to
potentiate NMDAR activation is that high systemic doses are
required to significantly elevate their availability within the
CNS because they are extensively metabolised and pass
poorly through the blood–brain barrier (D’Souza et al. 2000).
Furthermore, existing synthetic glycine-B site agonists have
relatively low affinity in comparison to the endogenous
agonists, glycine and D-serine (Milan 2002, Bräuner-Osborne
et al. 2000). Indeed, it has been argued that the simple
molecular structure of glycine in itself poses a limitation on
the development of novel synthetic analogues (Milan 2002).
Alternatively, glycine-B site activation can be enhanced
indirectly through pharmacological blockade of glycine
transporter 1 (GlyT1). GlyT1 is a major reuptake regulator
of glycine concentration at glutamatergic synapses (Aragon
and Lopez-Corcuera 2005) and is co-localised with
NMDARs (Attwell et al. 1993). Its normal physiological
role and anatomical localisation indicate that pharmacological
inhibition of GlyT1 would be a highly effective strategy to
increase glycine-B site occupancy, overcoming the limitations
of systemic treatment with glycine-B site agonists/partial
agonists as described above. Amongst the growing number of
GlyT1 inhibitors available, some have been shown to possess
the pre-clinical profile of putative anti-psychotics and are
currently undergoing clinical evaluation (Lechner 2006).
However, there is until now only limited evidence for their
potential pro-cognitive effects in non-pathological condi-
tions. The most promising GlyT1 inhibitor in this regard is
SSR504734, which has been shown to reverse the social
recognition impairment in rats induced by neonatal phency-
clidine treatment (Depoortère et al. 2005, Harich et al. 2007)
and to enhance pre-pulse inhibition (PPI) in a mouse strain
(DBA/2) with intrinsic sensorimotor gating deficiency
(Depoortère et al. 2005). PPI is often taken as a measure of
sensorimotor gating, which refers to a form of early-
attentional control in selective information processing, central
to the prevention of sensory overload (Graham 1975,
Swerdlow et al. 2000). Impaired PPI may be linked to other
cognitive deficits, and, therefore, restoration of deficient PPI
may alleviate such associated cognitive dysfunctions. There
is also recent evidence suggesting that the PPI magnitude
correlates with mnemonic performance in various learning
tasks (Giakoumaki et al. 2006, Bitsios et al. 2006), suggest-
ing that PPI enhancement may be a predictor of pro-cognitive
properties. This lends further support to the hypothesis that
SSR504734 may possess pro-cognitive potential.
The present study aimed to extend the behavioural
assessment of SSR504734 in cognitive function (Depoortère
et al. 2005) to working memory function in normal mice as
a test of the drug’s promnesic potential in non-pathological
conditions. Here, working memory was assessed using an
automated operant continuous delayed alternation proce-
dure that readily allows the manipulation of delay intervals
between successive trials, thus varying the retention
demand on working memory function.
Materials and methods
Subjects
The subjects were 31 naïve adult male C57BL/6 mice bred
in the specific pathogen-free breeding facility (ETH Zurich
Laboratory of Behavioural Neurobiology, Schwerzenbach,
Switzerland). They were weaned at post-natal day 21 and
caged in groups of unisex littermates until 10 weeks old,
when they were transferred to single caging in Type II
cages (Techniplast, Milan, Italy). The animals were main-
tained in a temperature- (21°C) and humidity-controlled
(55%) vivarium under a 12:12 h reversed light–dark cycle
(lights on at 1900 h). Food and water were provided ad
libitum until 1 week prior to behavioural training. Behavioural
testing took place in the dark phase of the cycle and
commenced when the animals were 12 weeks old. During
the course of the experiment, the animals were maintained on
a 23-h food deprivation regime, with their body weight
reduced to not less than 85% of their ad lib weight. Water was
available throughout.
The experimental manipulations and procedures de-
scribed here had been previously approved by the Zurich
Cantonal Veterinary Office. All procedures conformed fully
to the ethical standards required by the Swiss Act and
Ordinance on Animal Protection and the European Council
Directives 86/609/EEC.
Apparatus
The experiments were conducted using four Habitest
System (Coulbourn Instruments, Allentown, PA, USA)
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operant chambers (Model E10-10), each placed inside a
ventilated and sound-attenuated chest. The internal dimen-
sions of each chamber were 31×25×33 cm, but an opaque
Plexiglas partition wall was installed to reduce the available
floor area to 15×25 cm. Illumination inside the chamber
was provided by a house light (2.8 W) positioned on the
panel wall 21 cm above the grid floor. Two food magazine
trays were mounted on the panel wall, each equipped with a
1.4-W light source mounted inside. They were separately
connected to two independent food pellet dispensers
(Model H14-22M-20) using 20 mg sucrose pellets
(BioServ, Frenchtown, NJ, USA) as food reward. Nose
poke responses (magazine entries) were detected by an
infrared beam positioned at the entrance to each food
magazine. The magazine trays were positioned on either
side of a retractable lever mounted in the middle of the
panel wall (Model H21-03M). A 2.8-W stimulus light was
mounted 10 cm directly above the lever. Two additional
transparent partitioning walls (5 cm long and 6 cm apart)
were mounted on either side of the retractable lever so that
the animal was required to take a detour to move between
the lever and either magazine tray.
Drugs
SSR504734 (2-chloro-N-[(S)-phenyl [(2S)-piperidin-2-yl]
methyl]-3-trifluoromethyl benzamide, monohydrochloride)
was donated by Sanofi-Aventis (Paris, France). The
compound SSR504734 was suspended in distilled water
containing 5% Tween 80 (see Depoortère et al. 2005). Both
SSR504734 and vehicle–control (5% Tween) solutions
were freshly prepared daily and injected via the intraperi-
toneal (i.p.) route 30 min before testing. The injected
volume was 10 ml/kg.
Acquisition of the delayed alternation task
Introduction of food deprivation
At the age of 10 weeks, the animals were singly housed
and maintained on an ad lib food regime for 1 week
prior to the commencement of the food deprivation. This
was introduced gradually, with a progressive reduction of
feeding time across 6 days (12, 6, 4, 2, 1, and 1 h).
Water was constantly available. At the same time, the
animals were familiarised with the reward pellets in the
home cage to minimise food neophobia when operant
training began. Operant training commenced on the next
day, and the animals were maintained with 1 h free
access to food per day throughout the experimental
period. The animals’ body weight was monitored daily
and was not permitted to fall below 85% of their ad lib
weight.
Magazine training
The animals were first habituated to the operant chambers
and allowed to consume food pellets freely from the food
magazines. Each session began with ten food pellets already
placed in each magazine tray. The house light and magazine
lights were switched on throughout the 20 min of the session.
Once all mice were reliably consuming the reward pellets,
they were trained to earn reward by alternating their
successive nose poke responses between the two magazines.
Nose pokes training with signalled alternation
Under the constant illumination of the house light, the session
(once per day) began with the illumination of one of the two
magazine trays. A nose poke into this magazine resulted in the
delivery of one reward pellet. This magazine stayed illuminated
for two additional seconds before being turned off, and at the
same time, the alternative magazine was then illuminated
awaiting for a nose poke response. Nose pokes directed at an
unlit magazine tray did not yield any programmed consequence.
The session ended with the cessation of the house light, either
when the animal had made 16 correct nose poke responses or
when 10 min had elapsed. When an animal had completed the
16 correct responses within the maximum time allowed on two
consecutive days, it was trained to press a lever following each
rewarded nose poke response in order to trigger the illumination
of the next appropriate food magazine (see below).
Lever press training with trial-discrete signalled nose pokes
alternation
With the house light on throughout, this training session (once
per day) began with the presentation of the lever, which
coincided with the illumination of the lever stimulus light
directly above. One lever press resulted in the retraction of the
lever, cessation of the lever stimulus light, and illumination of
one of the two food magazines. Upon a nose poke to the
illuminated magazine, one reward pellet was delivered to that
magazine tray. The magazine light was then switched off after
2 s, and the next trial commenced with the presentation of the
lever signalled by the illumination of the lever stimulus light.
Nose pokes into an unlit magazine tray would not yield any
programmed consequence. The session was terminated with
the cessation of the house light when either 16 trials had been
completed or 10 min had elapsed. Delayed alternation
commenced the day after the animals had completed the
session within the maximum time on two consecutive days.
Baseline delayed alternation training
In the delayed alternation task, the animals were required to
alternate successive nose pokes between the two food
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magazines to earn a reward. This essentially followed a
“win-shift” rule, by which the correct response on a given
trial was to shift away from the previous rewarded
response. Choice accuracy thus depended on memory of
the last rewarded response. The information relevant to the
solution was trial dependent; hence, the task taxed one key
aspect of working memory function (Honig 1978). The
retention demand on working memory was manipulated
here by varying the delays (i.e. the inter-trial intervals)
between a (rewarded) response to the next choice.
The present delayed alternation task adopted a “two food
magazines and one lever” configuration, which differs its
design from the conventional trial-discrete non-matching-
to-sample operant working memory task based on a “two
levers and one food magazine” configuration (e.g. Dunnett
1993). However, this set-up was deliberately chosen
because our intention to mimic the T-maze continuous
delayed alternation procedure (e.g. see Marquis et al. 2007),
whereby the animals were required to alternate their
successive arm entries between the left and right choice
stems on a T-maze to obtain food reward. The continuous
nature of this task design was preserved in our operant
procedure, such that the response on a give choice trial
served effectively as the sample run of the following choice
in accordance with the non-matching rule. This design has
also been adopted previously in delayed non-matching-to-
sample tests (e.g. Aggleton et al. 1986, 1992, Yee and
Rawlins 1994). Here, the use of a correction trial (see
below) further ensured that correct choice behaviour would
also be consistently guided by a win-shift strategy.
A schematic of the delayed alternation test procedures is
provided in Fig. 1. With the house light on, each daily
session began with an initial “forced” trial, in which a
randomly selected magazine was illuminated. A nose poke
into this magazine resulted in the delivery of a reward
pellet. The magazine light remained on for two additional
seconds, followed by the initiation of the inter-trial interval
(ITI) preceding the first “choice” trial. A choice trial began
with the presentation of the lever and the simultaneous
illumination of the lever stimulus light, while both
magazine lights remained off. A lever press resulted in the
retraction of the lever, cessation of the lever light, and the
illumination of both magazines. A correct nose poke
response was followed by the immediate delivery of a
reward pellet, cessation of the alternative magazine light,
and the continual illumination of the chosen magazine light
for 2 s, followed then by the next ITI. On the other hand, an
incorrect choice resulted immediately in the cessation of all
magazine lights and a 5-s time-out period, during which the
house light was switched off and the lever remained
retracted. At the end of the time-out period, a forced trial
using the previous correct magazine was administered as
described above (also see Fig. 1). This was then followed
by the appropriate ITI prior to the initiation of the next
choice trial.
At the beginning of baseline training, all animals were
trained using an ITI of 1 s, with each session consisting of a
maximum of 12 choice trials to be completed within a
maximum of 10 min. Animals that consistently failed to
complete the 12 trials within the allotted time were
excluded from further testing. Otherwise, when choice
accuracy achieved ≥90% correct on two consecutive daily
sessions, a variable ITI procedure was introduced. Within a
session, the ITI varied between one of two possible delays
counterbalanced amongst the 12 trials. Over the first 4 days,
the ITI was either 1 or 4 s. Over the next 4 days, the ITI
was either 1 or 8 s. This allowed us to confirm and to
Fig. 1 Schematic illustration of the delayed alternation task. The
session began with the presentation of the centrally located lever, the
depression of which led to the start of a “forced trial”, in which one of
the two food magazines was illuminated waiting for a nose poke
response. Upon detection of a nose poke into one of the two
magazines, a food pellet was delivered into this magazine, and the
first ITI delay was initiated. During the ITI period, the lever remained
retracted and the magazine lights were off. At the end of the ITI, the
lever was presented, and its depression was followed by its retraction
and illumination of both magazines. Nose poke into the magazine
alternative to the one that yielded a reward now resulted in the
delivery of a reward (correct response). Nose poke into the magazine
that previously yielded a reward (incorrect response) was followed by
a 5-min “time-out” and then the presentation of a forced trial, in which
only the correct magazine was illuminated. Upon a nose poke into this
magazine, the programme resumed to the next appropriate ITI period,
followed then by a choice trial. Response latency was defined as the
time between lever press that triggered the magazine lights and the
magazine entry (nose poke), which constituted to an explicit choice
374 Psychopharmacology (2009) 202:371–384
identify the sensitivity of the task to increasing ITI within
sessions. A total of 17 mice reached this stage of training,
and they were then given 2 days of rest before the next
phase of testing with compound SSR504735.
Experiment 1: effects of SSR504734 on delayed alternation
(1- vs 4- vs 8-s delays)
We started by evaluating the effect of systemic SSR504734
on performance in the delayed alternation task in two delay-
function experiments. We elected to focus first on the
specific dose of 30 mg/kg i.p. because this was found to be
behaviourally effective by Depoortère et al. (2005) and
because it is also consistent with our impression obtained
from initial pilot studies with this compound (unpublished
data by P. Singer, J. Feldon and B.K. Yee).
In experiment 1, the delay function included three
possible ITI delays: 1, 4 and 8 s, inter-mixed across the
12 choice trials per session. On day 1, all animals were
given a vehicle injection 30 min before delayed alternation
training to familiarise them with the injection procedure.
The animals were subdivided into two groups—balanced
with respect to their baseline performance (on day 1). Over
the next 3 days, one group received daily pre-treatment of
SSR504734 at 30 mg/kg (n=8) and the other of vehicle
injection (n=9). One SSR504734-treated subject was
excluded because it failed to complete the 12 trials on the
first two tests days. At the end of this experiment, the
animals were given 2 days of rest before they were tested
again in experiment 2. However, another mouse (from the
vehicle group) died in this period, leaving a total of 15 mice
available, before experiment 2 commenced.
Experiment 2: effects of SSR504734 on delayed alternation
(1- vs 8- vs 12- vs 16-s delays)
In experiment 2, the delay function included four possible
ITI delays: 1, 8, 12, and 16 s, inter-mixed across the 16
choice trials per session. First, animals were given one
session of pre-training, in which they all received a vehicle
injection 30 min before the test (as in experiment 1). The
animals (n=15) were then subdivided into two new
subgroups in order to counterbalance their previous drug
experience in experiment 1. Namely, half of SSR504734-
treated animals in experiment 2 had received SSR504734 in
experiment 1 and the other half vehicle in experiment 1;
and half of vehicle-treated animals in experiment 2 had
received SSR504734 in and the other half vehicle in
experiment 1. This allowed us to gauge the possible effects
of previous experience with the drug. The two new groups
(SSR504734: n=7, vehicle: n=8) received either daily pre-
treatment of SSR504734 (30 mg/kg, i.p.) or vehicle
solution as described above. Drug testing lasted for three
consecutive days, after 1 day of training with vehicle
injection in all animals (as described in “Experiment 1:
Effects of SSR504734 on delayed alternation (1- vs 4- vs
8-s delays)”). After this, the animals were again given a
break of 2 days prior to the next experiment.
Experiment 3: dose–response analysis of SSR504734’s
effect in delayed alternation
We then conducted a dose–response analysis of SSR504734
(0, 3, 10 and 30 mg/kg) focussing on the minimal delay of
1 s and the extended delay of 12 s. All subjects had
completed experiments 1 and 2 before. On day 1, all
animals received a vehicle injection as described before for
a practice session. Over the following 4 days, a Latin
square design was adopted to balance the order of drug
doses across subjects (n=15). Each daily session consisted
of 12 choice trials, with half of the trials following a 1-s ITI
delay and the other half a 12-s delay. A maximum time of
10 min per session was allowed. No further animals were
excluded for not completing sessions.
Dependent measures and statistical analysis
Working memory performance was indexed by percent
correct choices, at each delay condition on each day. In
addition, the number of nose pokes recorded during the ITI
delays on a given day was also calculated and separately
analysed. All statistical analyses were carried out using
SPSS® for Windows™ (version 13) on a PC running the
Windows XP (SP2) operating system. Parametric analyses
of variance (ANOVA) were performed with the between-
subject factors, drug and previous drug experience, and the
within-subjects factors, delays and days (in “Experiment 1:
effects of SSR504734 on delayed alternation (1- vs 4- vs
8-s delays)” and “Experiment 2: effects of SSR504734 on
delayed alternation (1- vs 8- vs 12- vs 16-s delays)”). In
experiment 3, the effect of drug dosage was investigated
using a Latin square design, and the factor of drug doses
was analysed as a within-subjects factor. Data interpretation
was further assisted by Fisher’s least significant difference
(LSD) post hoc comparisons and the use of restricted
ANOVAs for determining the locus of the significant
effects. A critical level of p<0.05 was set for all statistical
analyses.
Results
Delayed alternation baseline training
Baseline training on the continuous delayed alternation task
began after the animals had successfully completed the pre-
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training of trial-discrete signalled nose poke alternation, in
which no mnemonic demand was required. The baseline
training on the continuous delayed alternation procedure
consisted of three consecutive phases, lasting for 15, 4 and
4 days, respectively. In the first phase, all ITIs were 1 s in
duration. As illustrated in Fig. 2A, choice accuracy
indexed by percentage of correct trials per daily session
was already above chance on day 1. Afterwards, perfor-
mance continued to improve steadily over days, achieving
criterion performance by the 15th day. Repeated measures
ANOVA of percent correct over the 15 days yielded a main
effect of days [F(14,238)=11.96, p<0.001; n=18).
In the second phase of baseline training, the ITIs varied
between 1 and 4 s. One animal failed repeatedly to
complete the 12 trials within the time limit and was
therefore excluded from the data analysis and from further
testing. The total number of mice was thereby reduced to
17. As shown in Fig. 2B, increasing the ITI to 4 s did not
result in any observable impact on choice accuracy in
comparison with the minimal 1-s delay condition. A 2×4
(delays×days) repeated measures ANOVA of percent
correct response failed to yield any significant effects.
In the third phase, the ITI within each daily session was
either 1 or 8 s. Choice accuracy was substantially reduced by
the extension of ITI to 8 s in comparison with the high choice
accuracy maintained at the 1-s delay condition (Fig. 2C). A
2×4 (delays×days) repeated measures ANOVA of percent
correct response yielded a highly significant effect of delays
[F(1,17)=36.69, p<0.001]. Neither the main effect of days
nor its interaction with delays achieved statistical significance.
The results from the baseline phase indicated that the 4-s
delay condition may be useful for assessing treatment
expected to impair working memory function. On the other
hand, delays of 8 s and above were sufficiently taxing for
normal animals and would therefore be suitable for the
detection of performance enhancing agents. The results of
phases 2 and 3 here also verified the stability of
performance at the minimal 1-s delay condition, even when
it was inter-mixed with trials of a higher mnemonic demand
as in phase 3. This design of varying delays within-session
enjoys a potential advantage over a between-session design
because the latter may lead to profound reduction of choice
accuracy, such that the subjects might give up on the task.
Experiment 1: delay function of 1, 4 and 8 s
One animal belonging to the SSR504734 condition repeat-
edly failed to complete the 12 trials within the time limit and
was therefore excluded from the data analysis of experiment
1 and discontinued from further testing. The final number of
subjects was therefore: SSR504734 n=7 and vehicle n=9.
As shown in Fig. 3A, performance of both SSR504734-
and vehicle-treated animals was maintained at a high
(∼90%) and comparable level at delays of 1 and 4 s across
the 3 days of drug test. Choice accuracy expressed as mean
percentage correct at different delays is depicted in Fig. 3A.
A group difference emerged at the longest delay of 8 s, with
SSR504734-treated animals outperforming the vehicle
controls. SSR504734 thus improved working memory
performance in a delay-dependent manner, i.e. only when
the demand on temporal retention was high.
These interpretations of the data were supported by a 2×
3×3 (drug×delays×days) ANOVA of percentage of correct
across the 3 days of test, which yielded a significant main
effect of delays [F(2,28)=21.01, p<0.001] and its interac-
tion with drug [F(2,28)=7.39, p<0.005]. Separate analyses
Fig. 2 Baseline delayed alternation training. (A) Acquisition of the
delayed alternation task under the minimal (1-s ITI) delay condition.
Performance was indexed by percent correct responses expressed as a
function of daily sessions. (B) Within-session comparison between trials
following a 1-s ITI and those following a 4-s ITI indicated little evidence
for an impact by this limited increase in retention demand. (C) Within-
session comparison between trials following a 1-s ITI and those
following a 4-s ITI yielded a significant main effect of delays (*p<
0.005) as confirmed by a 2×4 (delays×days) repeated measures ANOVA
of percent correct per day (n=17). All values refer to mean±SEM
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restricted to each delay condition indicated that SSR504734
significantly enhanced choice accuracy only at 8-s delay
[F(1,14)=6.88, p=0.02] but not at the two shorter delays.
Furthermore, at the critical delay of 8s when SSR504734
treatment exhibited a positive effect on performance, the
controls were still able to maintain performance above
chance (p<0.05 based on one sample t test). This suggested
that the superior performance by the SSR504734 group
could not be attributed to non-performance in the control
group at this particular delay condition. The effects of the drug
on performance did not appear to depend on days: neither the
main effect of days nor any of its interactions achieved
statistical significance. Indeed, analysis of data derived from
day 1 only (when the SSR504734-treated mice were receiving
the drug for the first time) were sufficient to yield a near-
significant effect of drug by delays interaction [F(2,28)=3.15,
p=0.058] and a main effect of delays [F(2,28)=5.60,
p<0.05]. When the comparison was restricted to the 8-s
delay condition on day 1, the drug effect again approached
statistical significance [F(1,14)=4.43, p=0.055], but did not
do so at the shorter delay conditions (F<1).
In addition, a separate analysis of the number of nose
pokes recorded during all ITIs (when both magazine trays
were not lit) was conducted. Such nose pokes were a
potential source of retroactive interference that might affect
working memory performance. A 2×3 (drug×days)
ANOVA of this measure did not yield any significant
effects. The frequency of nose pokes during ITIs was stable
across days and comparable between treatment groups. The
mean numbers of ITI nose pokes (±SEM) per daily session
were: SSR504734=59.3±7.1, vehicle control=62.1±4.7.
Experiment 2: delay function of 1, 8, 12 and 16 s
In the second delay-function experiment, the temporal
demand of retention was increased by extending the delay
up to 16 s. Again, 3 days of drug test were conducted
following 1 day of vehicle injection practice session in all
subjects. The subjects’ previous drug experience (in
“Experiment 1: Effects of SSR504734 on delayed alternation
(1- vs 4- vs 8-s delays)”) was counterbalanced in the
allocation of drug condition in experiment 2. Thus in each
drug condition here, there were subjects that had received the
drug in experiment 1 and subjects that did not. Prior drug
experience in experiment 1 was included as a between-subject
factor in the analysis of the present data set, but this factor was
excluded in the final analysis because it did not achieve
statistical significance either as a main effect or interaction.
As depicted in Fig. 3B, SSR504734 again selectively
enhanced choice accuracy at longer delays of 12 and 16 s.
The drug was, however, no longer effective at the 8-s delay
condition (c.f. “Experiment 1: Effects of SSR504734 on
delayed alternation (1- vs 4- vs 8-s delays)”), yet the
general impression of a performance enhancing effect by
SSR504734 was essentially replicated. Under the more
extended delays of 12 and 16 s, the vehicle group was no
longer able to sustain above chance performance (based on
one sample t test), whereas the SSR504734 group main-
tained performance at about 70% correct.
These interpretations of the data were supported by a 2×
4×3 (drug×delays×days) ANOVA of percent correct
responses, which yielded a significant main effect of drug
[F(1,13)=8.50, p<0.02], delays [F(3,39)=19.10, p<0.001]
and their interaction [F(3,39)=3.45, p<0.05]. Again, there
was no statistical evidence that performance varied signif-
icantly across days: Neither the main effect of days nor its
interactions achieved statistical significance. Additional
restricted analyses at each delay condition confirmed that
SSR504734 treatment significantly enhanced choice accu-
racy when the delay was extended to 12 s [F(1,13)=8.48,
p<0.02] and 16 s [F(1,13)=7.39, p<0.02].
Analysis of the number of nose pokes made during ITI
delays per daily session by a 2×3 (drug×days) ANOVA
again yielded no significant effects. The mean numbers of
nose pokes (±SEM) per daily session were: SSR504734=
106.9±10.8, vehicle control=102.4±9.8.
Experiment 3: dose–response analysis
Finally, we conducted a dose–response analysis across
doses: 0, 3, 10 and 30 mg/kg by focussing on the minimal
Fig. 3 Effects of systemic SSR504734 on the delayed alternation
task. Two separate delay-function experiments (experiments 1 and 2,
depicted in A and B, respectively) were conducted to examine the
effects of SSR504734 on delayed alternation performance. Animals
used in experiment 2 were previously tested in experiment 1. Drug
experience was fully counterbalanced (see “Materials and methods”).
Choice accuracy in each experiment was indexed by percent correct
(average across three drug test days) and illustrated here as a function
of ITI delays based on data obtained on three testing days. In both
experiments, SSR504734 significantly improved choice accuracy in
comparison to vehicle treatment at longer delays. Significant between-
groups difference at *p<0.05. Error bars refer to ±SEM
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delay of 1 s and the extended delay of 12 s to ascertain whether
a positive drug effect might also be identified at lower doses.
The animals from experiments 1 and 2 (n=15) were employed
here in a Latin square design to best counterbalance across
drug doses in a within-subject manner.
SSR504734 dose dependently enhanced choice accuracy,
but this effect was most clearly demonstrated in the 12-s
delay condition (Fig. 4). The efficacy of the highest dose
(30 mg/kg) was again confirmed here, with the 10-mg/kg
dose producing an intermediate level of enhancement.
These contrasted with the lack of effect at the lowest dose
of 3 mg/kg.
A 4×2 (drug doses×delays) repeated measures ANOVA
of choice accuracy yielded a significant main effect of drug
doses [F(3,42)=5.76, p<0.005] and delays [F(1,14)=
241.43, p<0.001]. Despite the tendency apparent in
Fig. 4, the interaction term failed to attain statistical
significance. However, separate analyses restricted to each
delay condition revealed a significant effect of drug doses
only in the 12-s delay condition [F(3,42)=3.93, p<0.05].
Planned contrast analysis of this significant effect indicated
that only the highest dose (30 mg/kg) significantly
enhanced performance in comparison with vehicle treatment
(p<0.05).
Separate one-way repeated measures ANOVAs of nose
poke frequency during ITI delays yielded no significant effect
of drug doses. The mean numbers of nose pokes (±SEM) per
daily session were: vehicle–control=60.2±6.0, 3 mg/kg=
63.1±6.1, 10 mg/kg=50.0±6.1, 30 mg/kg=65.6±7.1.
As a further test of the robustness of our results here,
which were obtained using a Latin square design and where
the factor dose was evaluated in a within-subject manner,
we performed an additional analysis restricted to the first
test day, in which the same factor was analysed as a
between-subject factor. In spite of the anticipated reduction
in statistical power, this nonetheless would allow an
assessment of whether the overall pattern of results
described above was already apparent on the first day. To
this end, a 4×2 (drug doses×delays) ANOVA was
performed on this restricted data set, which revealed a
pattern of results almost identical to the overall analysis
across the four test days. The analysis yielded a significant
effect of delay F(1,11)=86.3, p<0.001] and of dose
[F(3,11)=3.83, p<0.05]. Post hoc LSD comparisons further
confirmed the efficacy of SSR504734 to enhance perfor-
mance at the highest dose (30 mg/kg) in comparison with
vehicle treatment (p=0.006). In the minimal 1-s delay
condition, choice accuracy across increasing dose (0, 3, 10
and 30 mg/kg) was: 83.3±3.9%, 95.8±3.9%, 91.7±3.9%
and 94.4±4.5%, respectively. In the 12-s delay condition,
the corresponding percent correct scores were: 41.7±7.3%,
50.0±7.3%, 54.2±7.3% and 77.8±8.4%, respectively.
Discussion
The present study sought to evaluate the promnesic
potential of SSR504734 on working memory functions
using an operant delayed alternation paradigm. Across three
experiments, the results revealed that SSR504734 reliably
enhanced working memory performance at a dose of
30 mg/kg. The robustness of this particular dose demon-
Fig. 4 Dose–response analysis of SSR504734 on delayed alternation
performance. The efficacy to enhance delayed alternation performance
by SSR504734 at three doses (3, 10 and 30 mg/kg) in comparison
with vehicle treatment was assessed for two specific ITI delays: at the
minimal 1-s delay condition (A) and the extended 12-s delay condition
(B). A Latin square design was employed to counterbalance drug
experiences across four drug tests days. Data presented are based on
4 days of drug test. A clear dose-dependent effect was observed at the
delay condition of 12 s: SSR504734 dose-dependently enhanced
choice accuracy (B). Whilst the dose of 3 mg/kg lacked any clear
effect, the highest dose employed here (30 mg/kg) was clearly
effective (*p<0.05 in comparison to vehicle condition and 3 mg/kg),
with the middle dose (10 mg/kg) producing an intermediate effect.
Error bars refer to mean±SEM
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strated here is in agreement with the report by Depoortère
et al. (2005) who also showed that the dose of 30 mg/kg
was consistently active across a number of behavioural
paradigms relevant for schizophrenia-related cognitive
deficits. In contrast, the lowest dose of 3 mg/kg was
essentially devoid of any efficacy in the present task.
The promnesic effect of SSR504734 probably stems
from the acute effect of the drug, although in each
experiment, animals received multiple injections of the
drug across daily sessions. The overall pattern of results in
experiment 1 was evident when animals were first
administered the drug on the first day of the experiment.
The outcome of experiment 2 did not depend on whether the
subjects were naïve to SSR504734 before the experiment. In
experiment 3, dose was varied over 4 days, and a response
was clear. In addition, the overall pattern of results of
experiment 3 was clearly evident on the first day of test.
Thus, the robustness of the dose–response analysis was
supported in that it did not depend on the uniqueness of the
Latin square design.
Our results therefore implied that systemic treatment of
SSR504734 had very limited long-term effect on the present
memory task. This may represent an advantage from the
perspective of a cognitive enhancing agent for the non-clinical
population, but could also be a disadvantage as a therapeutic
agent against chronic and persistent cognitive deficiency.
The positive effect of SSR504734 on choice accuracy
expressed itself in a delay-dependent manner. This suggests
that the drug did not indiscriminately elevate performance
but was most effective when the delay condition was
sufficiently taxing. We manipulated task difficulty primarily
by varying the task’s retention demand. In experiment 1,
the drug was only effective at 8-s delays when performance
of the controls began to deteriorate drastically, while
remaining above the level of performance expected by
chance alone. In experiment 2, although the drug appeared
ineffective under the same delay conditions, its ability to
improve performance was clearly evident at extended
delays of 12 and 16 s and at a range at which the control
failed to exceed the level of performance expected by
chance alone. We have no explanation for the drug’s lack of
efficacy in experiment 2 at the 8-s delay condition, which
contrasted with its demonstrated effect in experiment 1.
However, we can exclude the possibility that repeated
dosing was the cause because the impact of prior drug
exposure in experiment 1 did not affect the outcome of
experiment 2. We can also exclude the introduction of the
12- and 16-s delays in experiment 2 as a likely reason
because the results obtained on the first test day (when the
novelty of these test conditions was maximal) conformed to
the outcome at 8-s delays in experiment 1. Thus, previous
experience of experiment 1 probably is important. Alterna-
tively, the 8-s delay condition was not functionally identical
in the two experiments because its presentation was inter-
mixed with different delay conditions. Nonetheless, this does
not detract from our general conclusion that SSR504734
affects working memory function under varying retention
demands.
From the end of the baseline training onwards, the
animals had maintained a consistently high level of choice
accuracy at performance at the minimal delay condition in
all three experiments. It suggests that the animals had
maintained the motivation to perform the task throughout
the session in spite of increasing task difficulty imposed by
the inclusion of more extended delays. This further
strengthens our conclusion that SSR504734 can enhance
mnemonic capacity with respect to memory retention and
retrieval. It would be highly relevant and interesting to
assess if the drug also possesses such potential when task
difficulty is achieved by other task parameters, for example
by varying the levels of interference.
One critical determinant of working memory function is
the ability to overcome or resolve interference (Jonides and
Nee 2006), and the present working memory task is no
exception. Indeed, the levels of interference might be
considerable. Every trial involved the same two choices
(or discriminanda), namely the two magazine trays, which
were identical in appearance except for their location in the
operant chamber. The repeated use of a single pair of
discriminanda in delayed matching-to-sample task (another
working memory test) is considerably more difficult in
comparison with the use of trial-unique discriminanda (e.g.
Yee and Rawlins 1998). It is because memories acquired
from preceding trials potentially interfere with the retrieval
of the relevant information on a given trial. This source of
(proactive) interference is, however, expected to reduce as
the delay interval between trials is lengthened.
Furthermore, the animals made additional nose pokes
into the inactive magazine trays (i.e. when the magazine
lights were off) during the retention intervals. These
responses represented another potential source of (retroactive)
interference, making accurate recall of the relevant past
information (location of the previous nose poke that generated
reward) more difficult. It is not possible to prevent such
responses in the present task design unless switchable
magazine doors are installed. An alternative to overcome this
interference is the “two levers and one magazine” configura-
tion where the discriminanda (i.e. the levers) can be retracted
during the inter-trial intervals. In contrast to proactive
interference resulting from preceding trials, retroactive inter-
ference is expected to increase as the delay interval between
trials widens.
Our data indicated that such retroactive interference was
largely similar for both drug and vehicle conditions; thus,
the possibility that SSR504734 enhanced performance here
solely by reducing the occurrence of interfering inter-trial
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nose pokes could be excluded. This assertion, however,
does not repudiate the possibility that SSR504734 may act
by reducing the functional impact of retroactive interference
on working memory function. For example, it may enhance
the perceptual distinctiveness or discriminability between
memory traces, thereby facilitating their selective retrieval.
If so, SSR504734 may be generally effective in facilitating
cognitive flexibility. This interesting possibility would cer-
tainly require additional tests in which interference is
explicitly manipulated (e.g. Yee and Rawlins 1998, Sanderson
et al. 2007).
The demonstrated delay-dependent effect of SSR504734
readily suggests that the drug has a promnesic impact on
the animal’s working memory capacity. It enhances the
ability to retain and retrieve information across the inter-
trial intervals in order to respond correctly on the next trial.
This characteristic of trial dependency is the hallmark of
working memory according to the relevant theories by
Honig (1978) and Olton (1979). The alternative win-shift
strategy would also be expected to require recall of trial-
dependent memory because throughout the sessions, both
magazine trays would be associated with rewards. In
addition, the task can be solved based on relative familiarity
(or recency) judgement because accurate solution can be
achieved by always selecting the relatively less familiar
magazine tray (Rawlins and Tsaltas 1983). This particular
strategy would be most prone to the accumulation of
interference and would predict that trials at the beginning of
the session are easier than those at the end. We attempted to
address this possibility by comparing performance between
the two halves within a session using our current data sets.
No significant difference in performance was however
evident between the two halves of a test session (data not
shown), although a consistent trend of lower accuracy in
the last half (by approximately 5% points) relative to the
first half was noted in all three experiments. This trend was
similarly observed regardless of drug conditions, suggesting
that the drug did not enhance performance primarily through
a reduction in within-session proactive interference.
One potential problem associated with sequential alter-
nation task (especially in an automated set-up) is the
possible adoption of a motor mediating strategy (Olton
et al. 1979), which may allow a solution that is essentially
free from any working memory demand. Here, this
possibility had been reduced by requiring the subjects to
press a centrally located lever to activate the availability of
a choice (illumination of both magazine lights), thus
ensuring that the mouse would always be in the same
location when the choice was presented. Furthermore, the
installation of partition walls between the lever and
magazines also reduced the use of simple motor pattern as
mediating strategy, although this possibility can never be
completely eliminated (see Stanhope et al. 1995). Most
critically, however, the use of mediating behaviour is
expected to assist performance at short rather than at long
delays (Rawlins and Tsaltas 1983). Given that SSR504734
was primarily effective at longer delays, the mnemonic
conclusion of this outcome is less likely to be weakened by
the interpretative problems associated with the potential use
of mediating strategy in such tasks.
Another relevant performance measure, as suggested by
an anonymous reviewer, is the animals’ response speed or
latency to make a decision in the context of task difficulty
as a function increasing delays. In our task, this corre-
sponds to the time between the lever press that triggered the
magazine lights and the nose poke that constituted the
choice selection (see Fig. 1). We elected to focus on
experiment 2 because it covered the widest spectrum of
delays (Fig. 5). A distinction between correct and incorrect
response was made, but there were insufficient data to
allow such a distinction at 1-s delays because of the high
level of performance in this condition. This analysis
revealed that response latency for correct response was
significantly higher than for incorrect response across
delays of 8–16 s [see Fig. 5B; F(1,13)=12.70, p>0.005].
Response latency for correct responses showed an inverted
U-shaped function against increasing delays. This led to the
emergence of a significant main effect of delays [F(3,39)=
3.55, p<0.05] in a repeated measure ANOVA of the latency
of correct responses across the four delay conditions, which
was solely attributed to the quadratic component [F(1,13)=
15.92, p<0.005; see Fig. 5A). Taken together, response
latency may therefore reflect effortful retrieval, which was
more demanding with increasing delays, but the animals
eventually shifted away from such effortful recall when the
delay was too high. In this respect, the non-significant
protraction of response latency by SSR504734 may be
relevant to the psychological impact of the drug on
cognitive functioning in general, even though this tendency
in itself may not fully account for the significant delay-
dependent enhancement of choice accuracy by SSR504734.
The present demonstration of a promnesic effect follow-
ing GlyT1 inhibition is of critical importance because until
now, clinical evidence on the pro-cognitive potential of
GlyT1 inhibition is limited to the endogenous GlyT1
inhibitor sarcosine in the treatment of schizophrenia (Tsai
et al. 2004, Lane et al. 2005). Moreover, although adjunct
glycine therapy was found to improve negative as well as
cognitive symptoms in schizophrenia patients (Heresco-
Levy et al. 1999, 2004, Javitt et al. 2001), studies in healthy
volunteers had questioned the ability of acute high-dose
glycine treatment to improve cognitive function in non-
pathological conditions. Recently, Palmer et al. (2008)
failed to obtain any evidence of cognitive enhancement in
healthy subjects following treatment, with high doses of
glycine (0.8 g/kg, per os) in measures of working memory,
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declarative memory, attention and perceptual processing.
Interpretation is further complicated by reports that a single
oral dose of glycine (0.8 g/kg, per os) can produce a
negative impact on cognition as demonstrated in the test of
mismatch negativity (Leung et al. 2008), in which
schizophrenia patients also exhibit a deficit (e.g. Umbricht
and Krljes 2005). Given that acute glycine administration at
0.1 to 0.2 mg/kg via the intraperitoneal route is highly
effective in substantially elevating plasma and CSF levels
of glycine within 2 h after injection (D’Souza et al. 2000),
the oral dose of 0.8 mg/kg described above is considerably
high in spite of the difference in the route of administration.
Why may high concentrations of glycine fail to enhance
and even impair cognition? First, excessive elevations of
glycine above the saturation threshold of glycine-B site can
result in NMDAR internalisation and may thereby lead to a
negative impact on overall NMDAR functions at the
network levels. This can result from either endogenous
glycine treatment (Nong et al. 2003) or GlyT1 blockade
(Martina et al. 2004). Secondly, elevated glycine levels
could also potentiate NMDARs located on inhibitory γ-
aminobutyric acid interneurons (Javitt et al. 1993), which in
turn would dampen overall excitatory neurotransmission at
the network levels. Thirdly, neuronal inhibition can also
result from the action of excessive glycine on low-affinity
inhibitory glycine receptors on pyramidal neurons (Laube
et al. 2002, Betz and Laube 2006, Rajendra et al. 1997).
These possible physiological responses to global elevation
of glycine concentration may imply that a moderate
increase in the glycine levels is more favourable (Singer
et al. 2007a, b).
Interestingly, Palmer et al. (2008) suggested that the lack
of a pro-cognitive effect following acute glycine treatment
may be due to individual variability in endogenous glycine
concentration. Given that the optimal elevation of glycine
for improving cognitive functions may differ considerably
between subjects, individual titration would be necessary to
show a consistent effect. The ability to adjust for the
optimal glycine concentration is further hindered by the
poor blood–brain barrier passage of glycine, which neces-
sitates massive dosing: A typical dose of 0.8 g/kg implies a
daily intake of glycine exceeding 50 g for an adult human
(Heresco-Levy et al. 1996, 1999, Javitt et al. 2001). The
potential side effects under such conditions must be
seriously considered. Besides the obvious respiratory
problems associated with exposure to high doses of glycine,
morphological changes in the cerebellum (e.g. a decrease in
density of astocytic fibres) have been reported in rats
following a 2-week glycine-rich diet (Shoham et al. 1999).
In view of the above limitations associated with direct
glycine intake, blockade of GlyT1 represents a superior
pharmacological approach to achieving selective potentiation
of NMDAR activation aimed at enhancing cognitive func-
tions. First of all, GlyT1 inhibitors are expected to readily pass
through the blood–brain barrier (e.g. Molander et al. 2007)
and therefore do not require exceptionally high doses to
reach their targets. Secondly, given the close anatomical
proximity between GlyT1 and NMDARs (Cubelos et al.
2005a, b), GlyT1 inhibition is ideally suited to achieve
elevation of the functionally most relevant local concentra-
tion of glycine—that is in the vicinity of the NMDAR’s
glycine-B site. Hence, this would maximise the functional
impact in terms of its desired action on NMDAR function,
without inducing excessive changes to the global concentra-
tion of glycine in the brain, which, as explained above, could
be counterproductive to the desired aim to enhance NMDAR
activities.
There is considerable evidence to suggest that effective
working memory function depends on both hippocampus
and pre-frontal cortex. However, the sensitivity of the
present task to hippocampal or pre-frontal cortex damage
Fig. 5 Response latency as a function of delay and response in
experiment 2. A Response latency (in seconds followed by ln-
transformation) as a function of delays in experiment 2 is represented
by separate curves, according to drug treatment conditions and
whether the response was correct or incorrect. In the 1-s delay
condition, four mice did not make any error and therefore represen-
tative group means for incorrect response latency cannot be calculated.
Error bars refer to ±SEM. Analysis of correct responses across all four
delay conditions by a 2×4 (drug×delays) ANOVA yielded a main
effect of delays [F(3,39)=3.55, p<0.05], which was associative with a
significant effect exclusively in the quadratic trend [F(1,13)=15.92,
p<0.005] according to an orthogonal contrast analysis, supporting the
presence of an inverted U-shaped effect. To examine the difference in
response latency between correct and incorrect response, the analysis
was restricted to the three higher delay conditions by a 2×2×3 (drug×
response type×delays) ANOVA. This yielded a main effect of delays
[F(2,26)=4.52, p<0.05] and response type [F(1,13)=12.70, p>0.005],
while the main effect of drug and its interaction terms did not achieve
statistical significance. B This depicts the mean response latency
averaged across the delays conditions of 8, 12 and 16 s, illustrating the
significant difference in response latency between correct and
incorrect responses (*p<0.05) Error bars refer to ±SEM
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has not been validated in mice. We have thus far validated
its sensitivity to systemic scopolamine treatment retrospec-
tively, using the same animals examined here: A clear dose-
dependent effect of scopolamine was observed (Fig. 6),
with significant impairment seen at 1 mg/kg (i.p.), and the
effect appeared to be independent of delays (c.f., Dunnett
et al. 1990). The pivotal contribution of NMDAR activity
and glutamatergic transmission in the hippocampus to
working memory has been suggested by Bannerman and
colleagues (e.g. McHugh et al. 2008; Bannerman et al.
2006, 2008). SSR50473 has been shown to potentiate
NMDAR-mediated excitatory post-synaptic currents in rat
hippocampal slice preparations (Depoortère et al. 2005),
and this is consistent with the suggestion that enhanced
NMDAR activation in the hippocampus had contributed to
the working memory enhancement seen in the present
study. Concerning the contribution of pre-frontal cortex to
working memory function, the primary focus is on dopami-
nergic activity, especially via dopamine D1 receptors (for a
review, see Brach 2004; Mehta and Riedel 2006), which may
at first glance seem unrelated to the pharmacology of
SSR50473. However, consistent with the relevance of pre-
frontal dopamine activity to working memory function,
SSR50473 has been reported to increase the extra-cellular
dopamine levels in pre-frontal cortex in vivo (Depoortère
et al. 2005) and to facilitate dopamine release in the nucleus
accumbens evoked by electrical stimulation of the baso-
lateral amygdala (Leonetti et al. 2006). It is therefore
possible that the more direct impact of SSR504734 on
NMDAR-mediated glutamatergic neurotransmission within
limbic cortices (e.g. hippocampus as well as amygdala) can
subsequently lead to the potentiation of dopaminergic
activity in pre-frontal cortex. Such concerted alternations in
multiple brain regions following systemic SSR504734
administration may be responsible for the enhancement in
working memory function demonstrated here. Further
dissections of the relative contributions between different
brain structures would necessitate additional experiments
involving local intracerebral drug infusion.
Conclusions
The present report demonstrated, for the first time, that the
enhancement of glycine availability in brain by inhibition
of its uptake via the GlyT1 transporter can lead to a clear
mnemonic improvement in non-pathological conditions. In
particular, it adds to previous reports of SSR504734’s
efficacy to restore the social recognition deficits in rats
induced by neonatal exposures to phencyclidine and to
alleviate the sensorimotor gating deficit intrinsic to the
DBA/2 mouse strain (Depoortère et al. 2005, Harich et al.
2007). The current novel finding thus substantiates the
potential use of GlyT1 inhibitors, and specifically
SSR504734, as adjunctive medication in the treatment of
cognitive and negative schizophrenia symptoms (Kinney
et al. 2003; Kinney and Sur 2005) and further extends its
potential application in other domains of cognitive well-being
(Lechner 2006) as highlighted by recent studies of GlyT1
knockout mice (Yee et al. 2006; Singer et al. 2007a, b).
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